As Associate Director of Clinical and Patient Products, Melissa Miller is a senior member of the CancerLinQ product team and oversees the strategy, development, and delivery of products and services for both clinical users and patients. Since joining the team in 2017, she’s been deeply involved in everything from; managing the initial launch of CancerLinQ Discovery®, overseeing the design and re-build CancerLinQ’s data processing pipeline, managing the various solutions for practice quality teams within SmartLinQ, and leading product marketing for all CancerLinQ products.
Melissa earned her bachelor’s degree in public health at The George Washington University with the plan of continuing her education to study medicine. Following her graduation, Melissa spent a few years learning and working alongside physicians and care teams in emergency rooms and private practices before making the decision to pursue an advanced degree in public health. She went on to earn her Masters in Public Health from Johns Hopkins University before joining a health technology start-up where she was responsible for designing and managing health behavior change programs for large employee populations. Melissa began to transition her focus into account management and eventually into product management where she oversaw the development and launch of several web and mobile consumer facing health and data tracking products. In Early 2017 Melissa learned about an opportunity on the product team at CancerLinQ, and the company’s mission caught her attention. Like most people, Melissa’s life has been personally impacted by cancer, and the idea of putting her product skills to work on such an important cause was too exciting to pass up.
In your position, how do you support the CancerLinQ mission?
It’s my job to bring the technology and design teams together to solve important problems for oncology care teams, with the goal of helping to improve the care of every cancer patient. In my role on our product team, I translate the challenges of our customers into the designs and solutions that our technology and data science teams build and deliver. All of the work that we do hinges on the mission of using technology and data to enhance the quality of cancer care and to make it possible to learn from the experiences of every cancer patient, everywhere.
What achievements at CancerLinQ are you most proud about?
Overseeing the design and build of the SmartLinQ QOPI Certification Pathway—which helps practices to automatically submit data for QOPI Certification—was a very rewarding project. Automated QOPI certification data submission was part of CancerLinQ’s original product vision when the company was founded, so it was very exciting to bring that concept into reality and watch it scale with our network.
What do you think is CancerLinQ’s biggest opportunity for impact?
Our biggest opportunities lie within the relationships we have built with the oncology community, and in the research and clinical value of the data we’ve collected. It is through our relationships with the oncologists, nurses and care teams in our network that we can identify, research, validate, and design solutions that can make a tangible impact on how patients are treated in a day-to-day clinical setting. Our impact is only as valuable as our customers believe it to be, so, nurturing these connections back into our network and learning from as many clinical users as possible will help to advance our product vision.
Additionally, the opportunity to change the shape of cancer care through learnings from the real-world data we have collected is immense and exciting. There is tremendous potential to inform the future of precision oncology with the insights we can learn from the experiences of every cancer patient and our data asset makes that opportunity a reality. We can use our data to ensure we’re delivering the right insights to the right clinicians at the right time, all with the aim of improving the quality of care for every cancer patient.
What are your team’s short- and long-term goals?
Currently, my team is focused on launching the first version of our Patient Journey/Patient Match solution, which will be CancerLinQ’s first ever clinician facing decision support tool, and our first tool to provide real-world evidence insights to clinicians at the point of care. In the long term, our goal is to build a comprehensive set of tools and services to help patients and providers in shared decision making at the point of care, including patient support tools, clinical guideline integrations, tumor board solutions, and clinical trial solutions
Looking forward, what are you looking forward to at CancerLinQ?
It has been fun and rewarding to watch our company grow and change over the past four and a half years. I’m looking forward to watching our continued evolution from a technology company for quality management and research into a technology and data company that builds comprehensive solutions for oncology care teams, oncology practices, oncology researchers, and cancer patients. We’re already laying the groundwork to transform our offerings with our investment in clinical tools for oncologists, and I’m excited to see how we realize this vision and transformation to serve the holistic needs of the oncology community for years to come.
We appreciate that you took time out of your schedule to talk with us, Melissa!
Thank you, it was a pleasure!